MedTrace Logo

Spatial Repellents for Malaria Control

NCT06122142 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2025-03-07

No results posted yet for this study

Summary

The primary objective of the study is to demonstrate and quantify the effectiveness of a spatial repellent (SR) product, in reducing malaria infection in humans under operational program conditions in a humanitarian assistance context. The design will be a cluster Randomized Control Trial (cRCT) representing an operational research study.

Conditions

Interventions

DEVICE

Transfluthrin - delivery by paid study personnel

Passive emanator with formulated transfluthrin, SR product will be delivered by paid study personnel

DEVICE

Transfluthrin - delivery by voucher system

Passive emanator with formulated transfluthrin, voucher which will be used to redeem for SR product(s) on a monthly basis for each head of household.

DEVICE

Transfluthrin - delivery by village health teams

Passive emanator with formulated transfluthrin, village health teams will distribute SR products.

Sponsors & Collaborators

  • S.C. Johnson & Son, Inc.

    collaborator INDUSTRY

  • Catholic Relief Services

    collaborator OTHER

  • Infectious Diseases Research Collaboration, Uganda

    collaborator OTHER

  • University of Notre Dame

    lead OTHER

Principal Investigators

  • John P Grieco, Ph.D. · University of Notre Dame

  • Suzanne Van Hulle, M.H.S. · Catholic Relief Services

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
6 Months
Max Age
59 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-05-31
Primary Completion
2025-05-31
Completion
2025-05-31

Countries

  • Uganda

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06122142 on ClinicalTrials.gov